产前皮质类固醇给药与儿童期呼吸系统疾病:一项回归断点研究
该研究基于加拿大不列颠哥伦比亚省2000至2016年31+0至36+6周单胎分娩孕妇所生儿童至2020年的随访数据,采用回归断点设计分析。在21965名儿童中,412名(1.9%)因下呼吸道感染住院,2287名(10.4%)诊断为哮喘。常规产前皮质类固醇给药与婴儿下呼吸道感染(风险比=0.95,95%CI:0.61,1.37)或儿童期哮喘(率比=1.08,95%CI:0.88,1.24)均无显著关联。
要点
- 在21965名儿童中,412名(1.9%)因下呼吸道感染住院,2287名(10.4%)诊断为哮喘。
- 常规产前皮质类固醇给药与婴儿下呼吸道感染无显著关联(风险比=0.95,95%CI:0.61,1.37)。
- 常规产前皮质类固醇给药与儿童期哮喘无显著关联(率比=1.08,95%CI:0.88,1.24)。
核心结论
- 未发现常规产前皮质类固醇给药影响儿童期远期呼吸系统疾病风险的证据。
研究设计与样本
- 采用回归断点设计的关联性人群队列研究,数据来源为加拿大不列颠哥伦比亚省。
- 纳入2000至2016年孕31+0至36+6周分娩的单胎妊娠孕妇所生儿童,随访至2020年,共21965名儿童。
- 以加拿大推荐的产前皮质类固醇给药临床切点孕34+0周为界,比较切点前入院(暴露概率较高,『暴露组』)与切点后入院(暴露概率较低,『非暴露组』)的妊娠。
- 婴儿下呼吸道感染住院采用对数二项回归分析,哮喘采用合并对数二项回归分析。
主要发现
- 队列共21965名儿童,其中412名(1.9%)因下呼吸道感染住院,2287名(10.4%)诊断为哮喘。
- 常规产前皮质类固醇给药与婴儿下呼吸道感染无显著关联:风险比=0.95(95%CI:0.61,1.37),风险差=每100例减少0.15例(95%CI:-1.30,0.99)。
- 常规产前皮质类固醇给药与儿童期哮喘无显著关联:率比=1.08(95%CI:0.88,1.24),至13岁时每100例超额5.49例(95%CI:-1.78,14.39)。
关键数值与推荐
- 加拿大推荐的产前皮质类固醇给药临床切点为孕34+0周。
- 主要结局为婴儿下呼吸道感染住院以及1至18岁期间住院或门诊哮喘诊断。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if routine administration of antenatal corticosteroids affects the risk of infant lower respiratory tract infection and/or childhood asthma. DESIGN: Linked population-based cohort analysed using a regression discontinuity design, which better controls for confounding than standard observational studies. SETTING: British Columbia, Canada. POPULATION: Singleton pregnancies with a maternal admission for delivery between 31 + 0 and 36 + 6 weeks' gestation from 2000 to 2016, with follow-up to 2020. METHODS: We estimated if risks of childhood respiratory outcomes differed between pregnancies admitted just before the Canadian recommended clinical cut-off for antenatal corticosteroid administration of 34 + 0 weeks gestation (i.e., with higher probability of exposure to antenatal corticosteroids; 'exposed') than those admitted just after this cut-off (i.e., with lower probability of exposure; 'unexposed') using log binomial regression (infant lower respiratory infection hospitalisation) and pooled log binomial regression (asthma). MAIN OUTCOME MEASURES: Infant lower respiratory tract infection hospitalisation, inpatient or outpatient asthma diagnosis at 1-18 years. RESULTS: In our cohort of 21 965 children, 412 (1.9%) infants were hospitalised with a lower respiratory tract infection and 2287 (10.4%) were diagnosed with asthma. Routine administration of antenatal corticosteroids was not associated with infant lower respiratory tract infection (risk ratio = 0.95 [95% CI: 0.61, 1.37], risk difference = -0.15 excess cases per 100 [95% CI: -1.30, 0.99]) or childhood asthma (rate ratio = 1.08 [95% CI: 0.88, 1.24] 5.49 excess cases per 100 by age 13 years [95% CI: -1.78, 14.39]). CONCLUSIONS: We found no evidence that routine administration of antenatal corticosteroids affects the risk of later childhood respiratory illnesses.
引用
- Hutcheon JA, Harper S, Cordingley MC, et al. Antenatal Corticosteroid Administration and Childhood Respiratory Morbidity: A Regression Discontinuity Study. BJOG. 2025. PMID: 40511481. doi:10.1111/1471-0528.18252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。